30.1 C
New York
Sunday, June 7, 2026

Tag: stimulation

newssourceFORcompanyinformationcontent1marketreleases

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut. 
A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

Fighting the Global Fertility Crisis! Taiwan Pioneers AI-Powered Embryo Selection Model — Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Breaking Through the "Blind Selection" Dilemma in Clinical Practice — TFC Taipei Fertility Center Introduces AI Scoring System to Help Infertile Couples End the...

SNF to Acquire Obsidian Chemical Solutions LLC

RICEBORO, Ga., Aug. 15, 2025 /PRNewswire/ -- SNF, the global leader in water-soluble polymers, today announced the acquisition of Obsidian Chemical Solutions LLC ("Obsidian"),...

BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer of home-use red light therapy...

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

The Brain Song Uses a Nasa-Inspired Gamma Wave Formula to Stimulate BDNF and Enhance Memory in 2025

Binaural Technologies’ The Brain Song offers a 17-minute gamma brainwave and BDNF support audio program for adults seeking natural memory, focus, and cognitive resilience without pills or complex routines in 2025. 
Binaural Technologies’ The Brain Song offers a 17-minute gamma brainwave and BDNF support audio program for adults seeking natural memory, focus, and cognitive resilience without pills or complex routines in 2025.

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

Peyto Reports Second Quarter 2025 Results

CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) --  Peyto Exploration & Development Corp. (TSX: PEY) ("Peyto" or the "Company") is pleased to report operating and financial results for the second quarter of 2025.

High Arctic Announces 2025 Second Quarter Results

High Arctic Announces 2025 Second Quarter Results

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Obtient l’Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l’Apnée Obstructive du Sommeil

INFORMATIONS PRIVILÉGIÉES
INFORMATIONS RÉGLEMENTÉES

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStimulation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers